Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

From weight loss to cancer drugs, subcutaneous injections are popular with patients for their convenience, potentially ...

Johnson & Johnson introduced its long-time IL-23 inhibitor plaque psoriasis and psoriatic arthritis drug Tremfya ... and AbbVie’s Skyrizi, approved for UC and Crohn’s disease in June, only ...

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its ...

Skyrizi is an effective treatment option for plaque psoriasis, Crohn’s disease, ulcerative colitis, and psoriatic arthritis. Success rates may vary depending on the condition being treated and ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

Stock analysts at Zacks Research decreased their FY2024 EPS estimates for AbbVie in a research report issued to clients and investors on Wednesday, January 15th. Zacks Research analyst S. Ganoria now ...

Direct-to-consumer drug ads are prohibited in almost all countries besides the US. By leading doctors to prescribe unnecessary and more expensive treatments at the request of their patients, they also ...

Crohn's the third indication for Skyrizi after psoriasis and psoriatic arthritis, and a key step in AbbVie's aim to grow the drug – already one of its top sellers with sales of almost $3 billion ...